Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus, With a 52-Week Open Label Extension
Conditions
Interventions
CR845 0.5 mcg/kg
Placebo
Locations
57
United States
Cara Therapeutics Study Site
Homewood, Alabama, United States
Cara Therapeutics Study Site
Huntsville, Alabama, United States
Cara Therapeutics Study Site
Bakersfield, California, United States
Cara Therapeutics Study Site 2
Beverly Hills, California, United States
Cara Therapeutics Study Site
Beverly Hills, California, United States
Cara Therapeutics Study Site
Chula Vista, California, United States
Start Date
February 20, 2018
Primary Completion Date
April 6, 2019
Completion Date
March 26, 2020
Last Updated
April 26, 2022
NCT02143648
NCT05575193
NCT04470154
NCT01660243
NCT03998163
NCT00494975
Lead Sponsor
Cara Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions